Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

NCT01208064 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

102

Enrollment

NETWORK

Sponsor class

Stopped based on IDMC decision

Conditions

Lung Cancer

Interventions

DRUG: pazopanib hydrochloride
OTHER: laboratory biomarker analysis
OTHER: pharmacogenomic studies
OTHER: pharmacological study
PROCEDURE: quality-of-life assessment

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC